Lamotrigine (Lamictal) has been approved for its fifth indication as an antiepileptic—this time as an add-on therapy to treat primary generalized tonic-clonic seizures in children two years of age and older and adults.
Lamotrigine (Lamictal) has been approved for its fifth indication as an antiepilepticthis time as an add-on therapy to treat primary generalized tonic-clonic seizures in children two years of age and older and adults. The drug is also approved as a maintenance treatment for bipolar I disorder in adults.
To see more Hot off the Press news articles, click here.
To go to the Drug Topics homepage, click here.
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.